Founder and CEO

Chief Medical Officer

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics?

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Medical Director, Pediatric Endocrinology – Medical Affairs

Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients with severe metabolic and endocrine disorders. The Medical Director, Pediatric Endocrinology – Medical Affairs will serve as the internal medical and scientific expert for hyperinsulinism and related endocrine disorders, leading the development and execution of the Medical Affairs strategy for RZ358 and the company’s endocrinology portfolio.

Sign up with Google

Sign in with Google